Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients w
|Effective start/end date
|4/28/21 → 11/30/25
- ALLOVIR, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.